Cargando…

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents

INTRODUCTION: The goal of this study was to examine the effects of selinexor, an inhibitor of exportin-1 mediated nuclear export, on DNA damage repair and to evaluate the cytotoxic effects of selinexor in combination with DNA damaging agents (DDAs) in cancer cells. RESULTS: Selinexor reduced the exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kashyap, Trinayan, Argueta, Christian, Unger, Thaddeus, Klebanov, Boris, Debler, Sophia, Senapedis, William, Crochiere, Marsha L., Lee, Margaret S., Kauffman, Michael, Shacham, Sharon, Landesman, Yosef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089403/ https://www.ncbi.nlm.nih.gov/pubmed/30112106 http://dx.doi.org/10.18632/oncotarget.25637

Ejemplares similares

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
por: Argueta, Christian, et al.
Publicado: (2018)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
por: Kashyap, Trinayan, et al.
Publicado: (2016)

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha, et al.
Publicado: (2015)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
por: Kashyap, Trinayan, et al.
Publicado: (2021)

Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms
por: Walker, Christopher J., et al.
Publicado: (2022)

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
por: Aboukameel, Amro, et al.
Publicado: (2018)

A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation
por: Cass, Michael, et al.
Publicado: (2022)

A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth
por: Rane, Chetan, et al.
Publicado: (2017)

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells
por: Yang, Jennifer, et al.
Publicado: (2014)

The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response
por: Yuan, Sheng, et al.
Publicado: (2023)

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
por: Breit, Megan N, et al.
Publicado: (2014)

Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma
por: Farren, Matthew R, et al.
Publicado: (2015)

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
por: Lassman, Andrew B., et al.
Publicado: (2022)

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
por: Marijon, Hélène, et al.
Publicado: (2021)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
por: Azmi, Asfar S., et al.
Publicado: (2017)

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
por: Garg, Manoj, et al.
Publicado: (2016)

Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia
por: Vitale, Candida, et al.
Publicado: (2023)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

The Nuclear Export Inhibitor Selinexor Inhibits Hypoxia Signaling Pathways And 3D Spheroid Growth Of Cancer Cells
por: Depping, Reinhard, et al.
Publicado: (2019)

Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth
por: Wettersten, Hiromi I., et al.
Publicado: (2014)

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
por: Martini, Silvia, et al.
Publicado: (2020)

Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor
por: Marcus, Joshua M., et al.
Publicado: (2015)

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3
por: Soung, Young Hwa, et al.
Publicado: (2017)

Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity
por: von Fallois, Moritz, et al.
Publicado: (2021)

421 A Phase 1 and Randomized Phase 2 Clinical Trial of Selinexor and Temozolomide in Recurrent Glioblastoma Among Adults: The Product of a Successful Team Science Approach
por: Chow, Frances, et al.
Publicado: (2023)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
por: Gounder, Mrinal, et al.
Publicado: (2021)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E
por: Fisher, Jack G., et al.
Publicado: (2021)

miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer
por: Martini, Silvia, et al.
Publicado: (2021)

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
por: Galinski, Basia, et al.
Publicado: (2021)

Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
por: Gravina, Giovanni Luca, et al.
Publicado: (2017)

Correction: Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
por: Gravina, Giovanni Luca, et al.
Publicado: (2019)

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
por: Garg, Manoj, et al.
Publicado: (2017)

Combating resistance to DNA damaging agents
por: Choi, Jung-Suk, et al.
Publicado: (2018)

DNA damaging agents in ovarian cancer
por: Barretina-Ginesta, Maria-Pilar
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ff9j6go1aqupsvlf8kto61072